Alsamman Khaldoon, El-Masry Omar S
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Dammam, P.O. Box: 2435, Dammam 31441. Saudi Arabia.
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Dammam, Dammam. Saudi Arabia.
Comb Chem High Throughput Screen. 2017;20(5):440-450. doi: 10.2174/1386207319666161226142822.
The development of new screening models for cancer therapy is indispensable for the improvement of cancer treatment, and for the creation of alternative possibilities in the field of chemotherapy. Screening models are routinely used to reduce the cost and resources involved in anticancer drug development. The value of any screening model will ultimately be ascertained by its ability to reliably predict the clinical response. Traditional in vivo screening models have been replaced with cell-based screening assays, and these cell-based models are under constant development to better mimic in vivo conditions. In this review, the developmental phases of anticancer screening models are discussed and exemplified, including the two-dimensional, threedimensional, cancer stem cell, and non-mammalian screening models. In addition, the use of new virtual screening tools as a model for anticancer drug development is highlighted.
开发用于癌症治疗的新筛选模型对于改善癌症治疗以及在化疗领域创造更多选择至关重要。筛选模型常用于降低抗癌药物研发的成本和资源消耗。任何筛选模型的价值最终都将由其可靠预测临床反应的能力来确定。传统的体内筛选模型已被基于细胞的筛选试验所取代，并且这些基于细胞的模型正在不断发展，以更好地模拟体内条件。在本综述中，将讨论并举例说明抗癌筛选模型的发展阶段，包括二维、三维、癌症干细胞和非哺乳动物筛选模型。此外，还将重点介绍使用新的虚拟筛选工具作为抗癌药物研发模型的情况。
